See more : Aqua Corporation Public Company Limited (AQUA.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Escon Japan REIT Investment Corporation (2971.T) Income Statement Analysis – Financial Results
- Cameco Corporation (0R35.L) Income Statement Analysis – Financial Results
- Universus Photo Imagings Limited (UNIVPHOTO.BO) Income Statement Analysis – Financial Results
- Biofrontera AG (0DOL.L) Income Statement Analysis – Financial Results
- Quilter plc (QLT.L) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma files 16 national patent applications to protect family of novel next-generation psychedelics
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has filed 16 national patent applications, including in the principal South East Asian markets to protect one of its key families of novel next-generation psychedelics with differentiated characteristics, “Family 1”. Family 1 drug candidates are...
Mindset Pharma expands IP portfolio with three non-tryptamine families of next-gen psychedelic compounds
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF), which is focused on creating novel psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders, revealed that through its discovery work, it has identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds....
Mindset Pharma CEO spotlights firm's intranasal formulation technology, robust IP portfolio and partnerships
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier told investors that in the last six months, the biotech company's efforts in the psychedelic space have begun to deliver impressive innovations, partnerships, and feedback reinforcing the firm's patent portfolio. The Toronto-based...
Mindset Pharma granted allowance for patent covering its short-duration novel psychedelic medications
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said the United States Patent and Trademark Office (USPTO) has granted allowance for the company's patent application covering its short-duration novel psychedelic medications for the treatment of central nervous system (CNS) disorders. Included in patent...
Mindset Pharma develops new patent-pending technology to deliver next generation psychedelic medicines intranasally
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) told investors it has developed a new, patent-pending technology, which can deliver its next generation of psychedelic medicines intranasally. The new platform leverages the company's unique platform technology, altering the pharmacokinetics profile of the active...
Mindset Pharma partners with the Center for Addiction and Mental Health for study comparing its novel compound MSP-1014 with psilocybin
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced that it has partnered with Toronto-based psychiatric research hospital the Centre for Addiction and Mental Health (CAMH) for a pre-clinical study on the company's novel psilocybin-like compound MSP-1014. The company said the study...
Mindset Pharma receives Notice of Allowance for psilocin derivatives patent application for treating central nervous system disorders
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's patent application number 17/387,845, titled, “Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS...
Mindset Pharma to Participate in Upcoming Conferences in June 2022
TORONTO, June 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma progresses plans for clinical trials of its advanced pre-clinical psychedelic MSP-1014
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has revealed that it is making headway in progressing its Family 1 lead clinical candidate, MSP-1014, towards clinical trials. The Toronto-based drug discovery company recently roped in a UK-based contract research organization (CRO), Clerkenwell Health, to prepare...
Mindset Pharma to Participate in Upcoming Conferences in May 2022
TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Source: https://incomestatements.info
Category: Stock Reports